Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    165
    ...
ATC Name B/G Ingredients Dosage Form Price
L01BC07 AZACITIDINE EVER PHARMA G Azacitidine - 100mg/100ml 25mg/ml Injectable powder for suspension 10,967,854 L.L
M02AA15 VOLDIC G Diclofenac sodium (diethylamine) - 10mg/g 1% Emulgel 172,012 L.L
N02BE01 PARACETAMOL PANPHARMA G Paracetamol - 10mg/ml 10mg/ml Injectable solution 1,959,322 L.L
R03BA02 BUDESONIDE ARROW G Budesonide - 0.5mg/2ml 0.5mg/2ml Inhalation suspension for nebuliser 1,342,499 L.L
A04AA01 ONDAKEY G Ondansetron (HCl dihydrate) - 8mg 8mg Tablet, film coated 4,489,778 L.L
B01AB12 HIBOR G Bemiparin Sodium - 7,500IU 7,500IU Injectable solution 2,198,526 L.L
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 198,578 L.L
C08CA01 AMLODIPINE ARROW G Amlodipine (besylate) - 10mg 10mg Capsule 462,282 L.L
C09DB07 CORONOPINE G Candesartan cilexetil - 8mg, Amlodipine - 10mg Capsule, hard 1,368,032 L.L
D04AB01 PROCOMIL G Lidocaine - 10% 10% Spray 139,760 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,308,903 L.L
J02AC03 VIROZOLE 200 G Voriconazole - 200mg 200mg Tablet, film coated 47,909,207 L.L
L01BC07 AZACITIDINE NEAPOLIS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
N02BE01 MAKOACHE G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 1,403,867 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
R03BA02 BUDENA G Budesonide - 50mcg/actuation 50mcg/actuation Inhalation suspension 823,775 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 62.5mg 62.5mg Tablet, film coated L.L
A04AA01 ONDANSETRON BIOGARAN G Ondansetron - 8mg 8mg Tablet, coated 1,307,559 L.L
A10BD02 GLYSTOR PLUS G Metformin HCl - 500mg, Glibenclamide - 5mg Tablet, film-scored 691,119 L.L
B05BB02 DEXTROSE 5% & SODIUM CHLORIDE 0.9% G Sodium chloride - 0.9g/100ml, Dextrose, H2O - 5g/100ml Injectable solution 226,036 L.L
C08CA01 AMLODIPINE BIOGARAN G Amlodipine (besylate) - 10mg 10mg Capsule 462,282 L.L
C09DX LOSANET AM PLUS G Losartan potassium - 100mg, Amlodipine - 10mg, Hydrochlorothiazide - 12.5mg Tablet 1,044,358 L.L
H02B PREDALONE PLUS G Prednisolone sodium phosphate - 10mg/5ml, Dexchlorpheniramine maleate - 2mg/5ml Syrup 890,776 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 686,704 L.L
J02AC03 VORICONAZOLE STRAGEN G Voriconazole - 200mg 200mg Tablet, coated 41,794,841 L.L
L01BC07 AZACITIDINE SHILPA G Azacitidine - 100mg 100mg Injectable powder 7,350,062 L.L
N02BE01 PARACETAMOL S.A.L.F G Paracetamol - 1000mg/100ml 10mg/ml Injectable solution 5,542,006 L.L
N05AH03 OLANZAPINE ARROW G Olanzapine - 5mg 5mg Tablet 670,577 L.L
R03BA02 AERONIDE G Budesonide - 400mcg 400mcg Capsule, inhalation 2,116,552 L.L
C02KX01 BOSENTAN ARROW G Bosentan (monohydrate) - 125mg 125mg Tablet, film coated L.L
    ...
    165
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025